NCT06962436 RAB Versus Ultrathin Bronchoscopy With VBN in the Diagnosis of PPNs
| NCT ID | NCT06962436 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Chest Hospital |
| Condition | Peripheral Pulmonary Nodules |
| Study Type | INTERVENTIONAL |
| Enrollment | 186 participants |
| Start Date | 2025-07-02 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 186 participants in total. It began in 2025-07-02 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate whether the diagnostic yield of robotic-assisted bronchoscopy is not inferior to that of the virtual bronchoscopic navigation combined with ultrathin bronchoscopy.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years, regardless of gender; 2. Patients with peripheral lung nodules of suspected malignancy on chest CT who require non-surgical biopsy; 3. Patients who voluntarily consent to undergo bronchoscopy and meet the requirements for the bronchoscopy; 4. Patients should understand the purpose of the trial, demonstrate good compliance with the examinations and follow-ups, and voluntarily participate in the clinical trial and sign the informed consent form. Exclusion Criteria: 1. Presence of contraindications for bronchoscopy, including: active massive hemoptysis; recent myocardial infarction or unstable angina; severe cardiac or pulmonary dysfunction; severe hypertension and arrhythmias; uncorrectable bleeding tendencies or severe coagulation disorders (such as platelet count \<60×10\^9/L), uremia; severe pulmonary artery hypertension; severe superior vena cava syndrome; intracranial hypertension; acute cerebrovascular events; aortic dissection or aneurysm; multiple bullae; extreme systemic exhaustion; 2. Patients with pure ground-glass nodules suspected of malignancy on chest CT; 3. Female patients who are breastfeeding, pregnant, or planning pregnancy; 4. Patients with electromagnetic active implantable medical devices; 5. Subjects allergic to anesthetics; or with a history of multiple severe allergies, hereditary allergy history; 6. Those who have participated in or are currently participating in drug clinical trials within 3 months before screening, or have participated in other medical device clinical trials within 30 days; 7. Any other conditions deemed unsuitable for participation in this clinical trial by the investigator.
Contact & Investigator
Jiayuan Sun
STUDY DIRECTOR
Shanghai Chest Hospital
Frequently Asked Questions
Who can join the NCT06962436 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Peripheral Pulmonary Nodules. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06962436 currently recruiting?
Yes, NCT06962436 is actively recruiting participants. Contact the research team at milozheng9140@163.com for enrollment information.
Where is the NCT06962436 trial being conducted?
This trial is being conducted at Jinan, China, Shanghai, China, Shanghai, China, Shanghai, China and 1 additional location.
Who is sponsoring the NCT06962436 clinical trial?
NCT06962436 is sponsored by Shanghai Chest Hospital. The principal investigator is Jiayuan Sun at Shanghai Chest Hospital. The trial plans to enroll 186 participants.